EXOZ
eXoZymes, Inc.
Healthcare — Biotechnology
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.
None
$5.83
(0.00%)
Price History
52-Week Range
Sign in to add EXOZ to a watchlist or set price alerts.
Fundamentals
| Market Cap | $78.89M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-1.15 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -185.84% |
| Debt/Equity | 76.23 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 56.2 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $18.40 |
| 52-Week Low | $6.33 |
| 50-Day Avg | $9.16 |
| 200-Day Avg | $11.03 |
| Avg Volume | 7.2K |
| Volume | 52.4K |
Performance Analysis
NEUTRALEXOZ presents a mixed picture with both positive and negative indicators.
+
Trading near its 52-week low ($6.33), which could present a value opportunity.
+
RSI at 56.2 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "none".
Recent News
Loading news...
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report